# Clinical experience with an online adaptive radiotherapy for prostate cancer: successful treatment time optimization

**Authors:** Hanna Malygina, Bryan Salazar Zuniga, Hendrik Auerbach, Marc Ries, Sven Knobe, Yvonne Dzierma, Jan Palm, Markus Hecht

PMC · DOI: 10.1186/s12885-026-15768-y · BMC Cancer · 2026-02-19

## TL;DR

This study shows that online adaptive radiotherapy for prostate cancer can be efficiently implemented with optimized treatment times using automated tools and improved imaging.

## Contribution

The study demonstrates practical time optimization strategies for online adaptive radiotherapy in prostate cancer treatment.

## Key findings

- Automated contouring reduced adaptation time by over 5 minutes per session.
- HyperSight imaging decreased total session time by 2.5 minutes on average.
- 93% of sessions were completed within 30 minutes, showing feasibility in routine practice.

## Abstract

Online adaptive radiotherapy (oART) can provide dosimetric advantages by accounting for daily anatomic changes, potentially improving target coverage and sparing of organs at risk. However, clinical adoption is sometimes limited by concerns over increased per-session treatment time. In this single-center study, we present 1.5 years of clinical experience focused on reducing the oART session time for prostate cancer patients.

We analyzed 1366 oART sessions from 69 prostate cancer patients treated on a Varian Ethos system between July 2023 and December 2024. We recorded (i) total session time — time between patient entry and exit from the treatment room, and (ii) adaptation time — time from start of the daily cone-beam-CT acquisition to completion of contour review/correction. We assessed the effects of two time-saving measures: automated contouring of the posterior rectal wall and installation of Varian HyperSight imaging. Statistical comparisons used the Mann–Whitney U test.

Automated posterior rectal wall contouring decreased mean adaptation time from 16.0 to 10.5 min (\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p<0.001$$\end{document}). Installation of HyperSight reduced mean total session time from 25.8 to 23.3 min (\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p<0.001$$\end{document}); the adaptation component improved by 0.5 min but not statistically significant (\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$p=0.053$$\end{document}). We achieved a total session time of \documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\leqslant 30$$\end{document} min for 93% of sessions.

Cone-beam-CT-guided oART is feasible in routine prostate cancer practice. Our findings indicate that a 30-minute time slot is sufficient for most adaptive prostate cancer treatments, and a median total session time of 23 minutes can be reached through workflow and imaging optimization. Clinics considering oART should note that treatment time decreases with operator experience, and targeted measures can further reduce session duration.

The online version contains supplementary material available at 10.1186/s12885-026-15768-y.

## Linked entities

- **Diseases:** prostate cancer (MONDO:0005159)

## Full-text entities

- **Diseases:** oART (MESH:D018489), bladder cancer (MESH:D001749), Cancer (MESH:D009369), prostate cancer (MESH:D011471), cervical cancer (MESH:D002583)
- **Chemicals:** oART (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12930564/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12930564/full.md

## References

7 references — full list in the complete paper: https://tomesphere.com/paper/PMC12930564/full.md

---
Source: https://tomesphere.com/paper/PMC12930564